CO-STRIMAX

This brand name is authorized in Nigeria.

Active ingredients

The drug CO-STRIMAX contains a combination of these active pharmaceutical ingredients (APIs):

1	Dutasteride UNII O0J6XJN02I - DUTASTERIDE
	Dutasteride reduces circulating levels of dihydrotestosterone (DHT) by inhibiting both type 1 and type 2, 5α-reductase isoenzymes which are responsible for the conversion of testosterone to DHT.
	Read more about Dutasteride
2	Tamsulosin UNII 11SV1951MR - TAMSULOSIN HYDROCHLORIDE
	Tamsulosin binds selectively and competitively to post-synaptic α1-adrenoreceptors, prevailingly their subtypes designated α1A and α1D. Thus relaxation of smooth muscles of the prostate and urethra is achieved, which leads to a reduction of tonus and an improvement of the urinary flow.
	Read more about Tamsulosin

Packages

This drug has been approved in Nigeria as follows:

Identifier	Form	Presentation	Description	Approval
A4-100392	Tablet	CO-STRIMAX TAB 0.5 mg; 0.4 mg 3x10	123 NF-PP-225985 CO-STRIMAX Tamsulosin and Dutasteride (0.5 mg/ 0.4 mg) Quantity in mg in 400 mg of pellets blend Tamsulosin HCl 0.40 mg USP, Dutasteride 0.50mg BP, Hypromellose ( HPMC E 5 ) 20MG,Mannitol 250MG, Sucrose 71.10MG, Crospovidone 10MG, Ethyl cellulose 40MG, Diethyl phthalate 8MG, Isopropyl alcohol Q.S, Dichloromethane Q.S Drugs Imported Products 3X10 Prescription Only Medicine (POM) 8/14/2021 EVANS THERAPEUTICS LIMITED, ABIMBOLA HOUSE, ABIMBOLA WAY, ISOLO INDUSTRIAL ESTATE, ISOLO LAGOS LAGOS 9062972898 info@evanstherapeutics.com SUNRISE REMEDIES PVT LIMITED, BLOCK NO. 2244, OPP. SHAH STREET, SANTEJ, TA. KALOL, DIST. GANDHINAGAR GUJARAT, INDIA., India	25/05/2023

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
G04CA52	Tamsulosin and dutasteride	G Genito urinary system and sex hormones → G04 Urologicals → G04C Drugs used in benign prostatic hypertrophy → G04CA Alpha-adrenoreceptor antagonists
Discover more medicines within G04CA52

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
NG	Registered Drug Product Database	A4-100392